BPMC Stock Overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Blueprint Medicines Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.78 |
| 52 Week High | US$85.67 |
| 52 Week Low | US$40.78 |
| Beta | 0.63 |
| 1 Month Change | 9.06% |
| 3 Month Change | -0.95% |
| 1 Year Change | -38.03% |
| 3 Year Change | -23.76% |
| 5 Year Change | -36.91% |
| Change since IPO | 153.21% |
Recent News & Updates
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Recent updates
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Most Shareholders Will Probably Find That The CEO Compensation For Blueprint Medicines Corporation (NASDAQ:BPMC) Is Reasonable
May 27Blueprint Medicines Corporation (NASDAQ:BPMC) Analysts Are Reducing Their Forecasts For This Year
Feb 18
Blueprint Medicines' (NASDAQ:BPMC) Wonderful 458% Share Price Increase Shows How Capitalism Can Build Wealth
Feb 14Blueprint Medicines Corporation's (NASDAQ:BPMC) Stock Is Going Strong: Have Financials A Role To Play?
Dec 23Are Blueprint Medicines's (NASDAQ:BPMC) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 27Shareholder Returns
| BPMC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | 0.8% | 2.8% |
| 1Y | -38.0% | 7.1% | -9.2% |
Return vs Industry: BPMC underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: BPMC underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| BPMC volatility | |
|---|---|
| BPMC Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BPMC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BPMC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 602 | Kate Haviland | https://www.blueprintmedicines.com |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
Blueprint Medicines Corporation Fundamentals Summary
| BPMC fundamental statistics | |
|---|---|
| Market Cap | US$2.86b |
| Earnings (TTM) | -US$717.56m |
| Revenue (TTM) | US$272.28m |
10.5x
P/S Ratio-4.0x
P/E RatioIs BPMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMC income statement (TTM) | |
|---|---|
| Revenue | US$272.28m |
| Cost of Revenue | US$748.58m |
| Gross Profit | -US$476.30m |
| Other Expenses | US$241.26m |
| Earnings | -US$717.56m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.99 |
| Gross Margin | -174.93% |
| Net Profit Margin | -263.54% |
| Debt/Equity Ratio | 21.6% |
How did BPMC perform over the long term?
See historical performance and comparison